FDA rejects AstraZeneca’s diabetes combo and demands more data

Damian Garde

The FDA wants to see clinical trial on AstraZeneca's new combination treatment, the company said, likely delaying a potential launch by more than a year.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS